Navigation Links
Interleukin Genetics Reports Second Quarter 2009 Financial Results
Date:8/13/2009

est for weight management that identifies an individual's genetic tendencies for weight gain and metabolism.
  • Granted License of Heart Health Genetic Test to LABEC Pharma. In April, the Company entered into a licensing agreement to permit LABEC Pharma to market and sell the Company's Heart Health genetic test throughout Spain and Portugal.
  • Amex Accepts Plan to Meet Continued Listing Standards. In May, Interleukin Genetics announced the Corporate Compliance Staff of the NYSE Amex LLC (the "Exchange") accepted the Company's plan to meet continued listing standards and granted the Company an extension to become compliant through December 31, 2009.

    • Scientific Highlights

    • Presented Data at the American Diabetes Association's Annual Meeting. In June, Interleukin Genetics presented research findings highlighting associations between perilipin gene variants and response to weight loss in overweight individuals at the ADA's 69(th) Scientific Sessions in New Orleans.
    • Co-Presented on Use of Biomarkers in Drug Development at BIO. Moderated and co-presented panel discussion on use of biomarkers in drug development in May at the BIO International Convention.

    Conference Call and Webcast Information

    Interleukin Genetics will host a live conference call and webcast today at 4:30 p.m. EDT to review the Company's new business developments and first quarter financial results. To access the live call, dial 877-440-5796 (domestic) or 719-325-4847 (international). The live webcast and replay access will be available on the Investors section of the Company's website at http://www.ilgenetics.com.

    About Interleukin Genetics

    Interleukin Genetics, Inc. (NYSE Amex: '/>"/>

    SOURCE Interleukin Genetics, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
    2. Interleukin Genetics to Present at the 2009 BIO Business Forum
    3. Interleukin Genetics Reports Fourth Quarter and Year End 2008 Financial Results
    4. Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii)
    5. Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing
    6. Interleukin Genetics Reports Third Quarter 2008 Financial Results
    7. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
    8. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
    9. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
    10. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
    11. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
    Other Biology Technology:Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 2Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 3Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 4Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 5Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 6Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 7Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 8Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 9Gq-coupled Receptor Assays Using FLEXstation 2Gq-coupled Receptor Assays Using FLEXstation 3Gq-coupled Receptor Assays Using FLEXstation 4Gq-coupled Receptor Assays Using FLEXstation 5Gq-coupled Receptor Assays Using FLEXstation 6Gq-coupled Receptor Assays Using FLEXstation 7FLIPR Calcium 3 Assay Kit Datasheet 2FLIPR Calcium 3 Assay Kit Datasheet 3